The "Ozempic babies" phenomenon
Within months of widespread GLP-1 prescribing, clinicians began noting unexpected pregnancies in women started on semaglutide for weight loss who had been considered subfertile. Some had PCOS, some had been trying without success for years, some weren't actively trying. The pattern was consistent enough that the term "Ozempic babies" entered the popular lexicon.
The biology underneath is straightforward: weight loss and improved insulin sensitivity restore ovulation in many women whose subfertility had a metabolic component. GLP-1 therapy is one of the most effective ways to produce these changes.
How GLP-1 restores ovulation
Anovulation in adults with overweight or obesity is mediated by:
- Insulin resistance, high insulin disrupts pituitary LH/FSH pulsatility and stimulates ovarian androgen production
- Excess androgens, particularly in PCOS, drive cyst formation and disrupt follicle maturation
- Inflammation, affects ovarian function and oocyte quality
- Leptin dysregulation, disrupts hypothalamic GnRH
GLP-1 therapy improves all of these. Insulin sensitivity rises substantially. Androgen levels often decline as insulin falls. Inflammation drops. Weight loss restores hypothalamic GnRH function. Ovulation often resumes within months.
PCOS specifically
Polycystic ovary syndrome is the leading cause of anovulatory infertility in women under 40. The metabolic phenotype of PCOS, insulin resistance, hyperinsulinemia, central adiposity, is precisely what GLP-1 therapy targets. Metformin has been the workhorse for decades. GLP-1 therapy is metformin's more powerful descendant.
Trial data in PCOS patients on semaglutide or tirzepatide show:
- Restored ovulation in 60-80% within 6 months
- Reduced androgens (testosterone, DHEA-S)
- Reduced LH:FSH ratio toward normal
- Improved menstrual regularity
- Improved fertility markers and pregnancy rates
Semaglutide for PCOS covers the protocol details.
Effects in men
In men, GLP-1 therapy may improve fertility through:
- Reduced obesity-related testosterone suppression
- Reduced estrogen excess from peripheral aromatization
- Reduced inflammation affecting sperm parameters
- Improved erectile function via vascular and metabolic improvement
Sperm parameters often improve modestly with substantial weight loss. The combination of GLP-1 therapy plus addressing low testosterone (where present) can substantially improve male fertility, though direct trial data is more limited than for women.
Pregnancy safety data
The safety of GLP-1 therapy during pregnancy is not well established. Animal studies have shown some embryotoxicity at high doses. Human data is limited and based on accidental pregnancies during therapy. Current guidance from manufacturers and most clinicians:
- GLP-1 therapy is not recommended during pregnancy
- Stop therapy at least 2 months before planned conception (one full half-life clearance plus margin)
- If pregnancy occurs while on therapy, stop immediately and consult provider
- Pregnancy registries are actively collecting data; longer-term safety profile is emerging
Stopping before conception
Semaglutide has a half-life of ~7 days. Five half-lives (35 days) eliminates 97% of drug. Most providers recommend stopping at least 2 months before active conception attempts to provide margin. For patients on tirzepatide (slightly shorter half-life), similar 2-month buffer.
The challenge: weight regain often begins within weeks of stopping therapy. Many patients planning pregnancy work with their provider on a coordinated stop and conception plan, with the understanding that some weight regain is likely between stopping and pregnancy onset.
After delivery
Postpartum return to GLP-1 therapy is generally safe once breastfeeding considerations are addressed. Limited data exists on GLP-1 transmission via breast milk; current general practice is to avoid during breastfeeding. After weaning, therapy can resume.
The clinical pearl: Restored fertility is a frequent unexpected finding on GLP-1 therapy in patients with metabolic-driven subfertility. Patients who do not want to become pregnant should use reliable contraception. Patients who do want to conceive should plan a coordinated stop with their provider.
Bottom line
GLP-1 therapy substantially improves fertility in many patients with weight-related and PCOS-related subfertility. The mechanism is restored ovulation through improved insulin sensitivity, reduced androgen excess, weight loss, and reduced inflammation. The medication is not used during pregnancy, but for patients trying to conceive, it can be part of pre-conception optimization with appropriate stop planning.